Her2 Detection
Her2 Detection - Related Videos
10:21
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
0 Views •
Cited by 3 •
2017
Fluorescence in-situ hybridization (FISH) is often required in combination with histopathology and molecular diagnostics for selection of therapy in personalized medicine. A novel non-cross-linking, formalin-free tissue fixative that allows high quality morphologic, molecular and FISH analyses from the same specimen by addition of a post-fixation step before FISH is presented.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
0 Views •
Cited by 8 •
2016
This manuscript describes clinical protocols for two next-generation sequencing panels. One panel interrogates hematologic malignancies while the other panel targets genes commonly mutated in solid tumors. Molecular classification of driver mutations in human malignancies offers valuable prognostic and predictive information.
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
0 Views •
Cited by 19 •
2017
Heterogeneous distribution of HER2-positive cells can be observed in a subset of breast cancers and generates clinical dilemmas. Here, we introduce a reliable and cost-effective protocol to define, quantify, and compare HER2 intra-tumor genetic heterogeneity in a large series of heterogeneously processed breast cancers.
09:10
Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce
0 Views •
Cited by 17 •
2010
This protocol describes a simple adhesive-tape-based approach for sampling of tomato and other fresh produce surfaces, followed by rapid whole cell detection of Salmonella using fluorescence in situ hybridization (FISH).
FAQs
The methods assess different biological features of the tumor. Immunohistochemistry evaluates HER2 protein displayed on the cell surface, whereas in situ hybridization examines HER2 gene signals in relation to a reference chromosome. Using these distinct measurements gives pathologists complementary evidence for tumor classification and can support treatment decisions when protein findings and gene-related findings require further clinical interpretation.
Immunohistochemistry contributes information about the amount of HER2 protein present on tumor-cell surfaces. This protein-level assessment helps pathologists classify a tumor as HER2-positive, HER2-negative, or potentially equivocal. Its clinical value comes from connecting receptor expression with decisions about targeted therapy, while uncertain staining results may require an additional testing approach before classification is finalized.
In situ hybridization evaluates gene-related evidence by detecting HER2 signals and comparing them with signals from a reference chromosome. This relationship helps identify increased HER2 gene copy number, including gene amplification. Because the method examines genetic information rather than surface protein alone, it provides a complementary basis for classifying tumors and resolving selected uncertain findings.
An equivocal result does not provide a sufficiently clear basis for assigning a tumor to the positive or negative categories. Additional testing can supply another type of evidence, such as protein-level or gene-related information, to clarify the classification. Resolving that uncertainty is important because the final interpretation may influence targeted therapy selection and treatment planning.
Pathologists interpret HER2 findings by using immunohistochemistry, in situ hybridization, or both as complementary approaches, depending on whether protein expression or gene copy number needs assessment. They then classify the tumor or pursue additional testing when the result is equivocal. This structured interpretation converts laboratory findings into clinically relevant information for diagnosis and therapy decisions.
HER2 detection is clinically useful when physicians need information to guide targeted treatment decisions in tumors associated with HER2. Its established relevance includes breast and gastric cancers, as well as other HER2-associated cancers. The findings can support diagnosis, help predict treatment response, and add clinically relevant information to the overall assessment of a patient.
The classification produced by HER2 testing can help determine whether targeted therapy should be considered and can contribute to predictions about treatment response. This makes accurate interpretation important beyond laboratory categorization alone. In medicine, the result links tumor biology with therapeutic planning and gives patients clinically relevant information about how their cancer may be managed.